CN115298210A - 用于治疗慢性移植物抗宿主病的抗体 - Google Patents

用于治疗慢性移植物抗宿主病的抗体 Download PDF

Info

Publication number
CN115298210A
CN115298210A CN202080095646.6A CN202080095646A CN115298210A CN 115298210 A CN115298210 A CN 115298210A CN 202080095646 A CN202080095646 A CN 202080095646A CN 115298210 A CN115298210 A CN 115298210A
Authority
CN
China
Prior art keywords
csf
antibody
versus
host disease
chronic graft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095646.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·欧尔德恩特里奇
M·迈尔斯
B·W·莫里森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syndax Pharmaceuticals Inc
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Priority to CN202610407661.9A priority Critical patent/CN122399012A/zh
Priority to CN202610407659.1A priority patent/CN122461447A/zh
Publication of CN115298210A publication Critical patent/CN115298210A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080095646.6A 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体 Pending CN115298210A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202610407661.9A CN122399012A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体
CN202610407659.1A CN122461447A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945842P 2019-12-09 2019-12-09
US62/945,842 2019-12-09
US202063110111P 2020-11-05 2020-11-05
US63/110,111 2020-11-05
PCT/US2020/064010 WO2021119128A1 (en) 2019-12-09 2020-12-09 Antibodies for the treatment of chronic graft versus host disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202610407659.1A Division CN122461447A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体
CN202610407661.9A Division CN122399012A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体

Publications (1)

Publication Number Publication Date
CN115298210A true CN115298210A (zh) 2022-11-04

Family

ID=76330540

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080095646.6A Pending CN115298210A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体
CN202610407661.9A Pending CN122399012A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体
CN202610407659.1A Pending CN122461447A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202610407661.9A Pending CN122399012A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体
CN202610407659.1A Pending CN122461447A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体

Country Status (11)

Country Link
US (2) US12552869B2 (cg-RX-API-DMAC7.html)
EP (1) EP4073100A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023506779A (cg-RX-API-DMAC7.html)
KR (1) KR20220123004A (cg-RX-API-DMAC7.html)
CN (3) CN115298210A (cg-RX-API-DMAC7.html)
AU (1) AU2020401551A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164126A1 (cg-RX-API-DMAC7.html)
IL (1) IL293705A (cg-RX-API-DMAC7.html)
MX (1) MX2022007029A (cg-RX-API-DMAC7.html)
PH (1) PH12022551401A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021119128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121219009A (zh) * 2023-05-17 2025-12-26 信达克思制药公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法
AU2024300057A1 (en) * 2023-07-23 2026-01-08 Incyte Corporation Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658236A (zh) * 2013-08-30 2016-06-08 Ucb生物制药私人有限公司 抗体
WO2018213665A1 (en) * 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CN102218070A (zh) * 2004-12-30 2011-10-19 索利吉尼克斯公司 用二丙酸倍氯米松和泼尼松治疗移植物抗宿主病和白血病
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
JP2010500283A (ja) 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
US20080114007A1 (en) 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトc−fms抗原結合性タンパク質
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
RU2547586C2 (ru) 2008-03-14 2015-04-10 Трансжене С.А. Антитело против csf-1r
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
KR102061358B1 (ko) 2011-10-21 2019-12-31 트랜스진 에스.에이. 대식세포 활성화의 조절
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
SG11201705484WA (en) 2015-02-09 2017-08-30 Ucb Biopharma Sprl Pharmaceutical formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658236A (zh) * 2013-08-30 2016-06-08 Ucb生物制药私人有限公司 抗体
WO2018213665A1 (en) * 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KYLIE A ALEXANDER 等: "CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 10, 26 August 2014 (2014-08-26), pages 4266 - 4280, XP055837036, DOI: 10.1172/JCI75935 *
SYNDAX PHARMACEUTICALS: "A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVD", pages 1 - 23, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/study/NCT03604692?a=7&tab=history#version-content-panel> *
SYNDAX PHARMACEUTICALS: "NCT03604692:A Phase 1/2 Study to Evaluate SNDX-6352 in Participants With Active cGVHD", HTTPS://CLINICALTRIALS.GOV/STUDY/NCT03604692?COND=CHRONIC%20GRAFT-VERSUS-HOST%20DISEASE&TERM=AXATILIMAB&RANK=5, 27 July 2018 (2018-07-27), pages 1 - 15 *

Also Published As

Publication number Publication date
EP4073100A4 (en) 2024-02-14
US20230035183A1 (en) 2023-02-02
PH12022551401A1 (en) 2023-08-23
JP2023506779A (ja) 2023-02-20
WO2021119128A1 (en) 2021-06-17
CN122461447A (zh) 2026-07-28
EP4073100A1 (en) 2022-10-19
US12552869B2 (en) 2026-02-17
MX2022007029A (es) 2022-08-15
KR20220123004A (ko) 2022-09-05
AU2020401551A1 (en) 2022-06-30
CN122399012A (zh) 2026-07-17
US20260132210A1 (en) 2026-05-14
CA3164126A1 (en) 2021-06-17
IL293705A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
JP2024038250A (ja) 抗pd-1抗体及び抗ctla4抗体によるがんの処置方法
TW202319068A (zh) 用抗tim-3抗體治療癌症之方法
EP3581585A1 (en) Vedolizumab for the treatment of fistulizing crohn&#39;s disease
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
JP2009541374A (ja) Copdを処置するためのcd20結合分子
US20220178930A1 (en) Anti-galectin-9 antibodies and uses thereof
TW202237184A (zh) 抗cd19組合療法
US20260132210A1 (en) Csf-1r antibodies for the treatment of chronic graft versus host disease
US20230131598A1 (en) Combination treatment for cancer
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2024156880A (ja) がんを処置するための抗lag3抗体の投薬レジメンおよび抗pd-1抗体との組み合わせ治療
JP2023515675A (ja) Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
KR20230095983A (ko) Gm-csf 길항제를 사용한 암의 치료
CN110582702A (zh) 使用il-17拮抗剂选择性治疗哮喘的方法
JP2023504679A (ja) インターロイキン-17(il-17)アンタゴニストを使用して扁平苔癬を治療する方法
JP2023541921A (ja) Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
EA052089B1 (ru) Антитела для лечения хронического заболевания &#34;трансплантат против хозяина&#34;
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
WO2025085792A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
HK40121853A (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination